ULTIPLE MYELOMA (MM) is a B-cell malignancy
characterized by the slow proliferation of malignant plasma cells within the bone marrow. In vivo, clusters of myeloma cells grow generally in the close vicinity of bone trabeculae and of their normal cellular partners, osteoblasts and osteoclasts.' Interestingly, both cells are present in increased numbers in MM,'-3 but their specific functions (bone resorption and formation) are targeted differently by tumor cells. Indeed, at the cell and tissue levels, osteoclastic resorption is stimulated, whereas bone formation is inhibited. This uncoupling process is responsible for lytic bone lesions, the common feature in all patients with MM: in contrast with observations in other B-cell malignancie~.~ Osteoblasts, which are of stromal origin, are normally involved in both bone formation by producing collagenic and noncollagenic proteins (osteocalcin), the major components of bone matrix, and bone resorption by producing factors necessary for the recruitment and then activation of new osteoclast^.^-^ Among these factors, those belonging to the gp130 family (interleukin-6 [IL-61 and its agonistic receptor gp80, leukemia-inhibitory factor [LW], IL-11, and oncostatin M [OSM]) play a major role.lO"' Notably, some of them (mainly, IL-6 and its receptor gp80) are essential MM cell growth factor^.'^"^ In mice, it has been established that the growth of primary plasmocytomas is dependent on physical contact with stromal cell feeder layers, and this required contact is partly mediated by CD44.I' In humans, the critical role of stromal cells in the pathogenesis of MM was first suggested by Caligaris-Cappio et all8 and then was extended by other^,'^-^^ showing that the microenvironment acts both via cell-to-cell, cell-to-extracellular matrix (ECM) contact and by the release of growth and differentiation factors. In particular, it has been established that adhesion of human myeloma cell lines to bone marrow stromal cells (BMSC) induces IL-6 triggering by BMSC.I9-" In this context, the functional role of adhesion molecules present on the myeloma cell surface has been in~estigated'~-~~ and, for some of them, clarified: CD49d (VLA4), expressed on all myeloma cells, and CD49e (VLAS), expressed only on immature myeloma cells, 25 
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fibronectin interactions. Osteocalcin production by MG63 and Saos-2 cells has previously been shown t o be dependent on 1,25-(OH)zD3. We demonstrate that XGI and XG6 cells reduced the amount of osteocalcin in MG63 coculture cell supernatants, a reduction that is partly mediated by a SOIUble factor and by cell-to-cell contact. Notably, whereas one of the myeloma cell lines, XG6, has lost its capacity t o stimulate IL-6 production by osteoblastic cell lines, both XGI and XG6 cell lines remain able t o reduce the osteocalcin amount, indicating that IL-6 and osteocalcin levels are regulated by t w o different pathways. In conclusion, these data strongly support the concept that the bone microenvironment is directly modified by contact with myeloma cells and are consistent with the characteristics observed in vivo in patients with MM patients, ie, abnormally high IL-6 and low osteocalcin levels, respectively. responsible for the adhesive interaction with the fibronectin produced by BMSC. Blockage of the VLA4, VLASJfibronectin interactions partially inhibits the triggering of IL-6 by stromal cell^.'^-^' Moreover, this interaction has been shown to be involved in final B-cell maturation and contributes to the Ig secretion.26 CD56 (NCAM), which mediates cell-tocell interaction by homotypic adhe~ion,'"'~ is expressed on normal plasma cells but is upregulated on myeloma ~e l l s .~~*~' Interestingly, several studies indicate that CD56 is no longer expressed in the final extramedullary phase of the disease, and that this loss of CD56 is believed to be responsible for the capacity of myeloma cells to spread out of the bone Until now, all the studies reporting the critical role of the bone marrow environment have been performed using longterm cultures of BMSC presenting a fibroblastic phenotype. Because the human osteosarcoma cell lines MG63 and Saos-2 share many properties with normal osteoblasts (alkaline phosphatase activity; secretion of osteocalcin and type I and 111 collagens, response to parathormone, 1,25-[OHIZD3, and ~ytokines),~'-~~ we used these cell lines as an in vitro model to examine the functional effect of myeloma cells on osteo-31 52 BARILLC ET AL blastic cells. Moreover, a recent study by Clover and Gowen3' leads to the conclusion that MG63 constitutes the most appropriate model for studying the regulation of osteocalcin by osteoblastic cells. Recently, Zhang et a136 have established myeloma cell lines named XG, the growth of which is dependent on exogeneous IL-6. In the present study, two of these IL-6-dependent myeloma cell lines, XG1 and XG6, were used to evaluate their potential effect on the IL-6 and osteocalcin production of the osteosarcoma cell lines.
MATERIALS AND METHODS
Antibodies. CD44 (J173), CD49 (HP2.1), CD49e (SAMI), CD54 (84H10), CD56 (T199), CD58 (AICD58). and anti-fibronectin (120.5) monoclonal antibodies (MoAbs) were purchased from Immunotech (Marseilles, France). CDlla (MHM24) was purchased from Dako (Glostrop, Denmark). CD106 (HAE-2a) was obtained from the Fifth Human Leukocyte Typing Workshop. For the study of the CD29 molecule, we used the MoAb K20 previously described.,' For blocking experiments, we used the blocking CD56 MoAb (2-13), which was a gift from Dr Engleman (Stanford Blood Center, Palo Alto, CA Cell culture. Human myeloma cell lines XG1 and XG6 were maintained in RPMI 1640 supplemented with 10% fetal calf semm (FCS), 2 mmol/L glutamine, 100 pg/mL streptomycin, 100 U/mL penicillin, 5 X m o m 2-mercaptoethanol, and 3 nglmL human recombinant IL-6 (rIL-6; Sandoz, Rueil-Malmaison, France). Human osteosarcoma cell lines were maintained in RPMI 1640 supplemented as described above but without IL-6 and were passaged at a ratio of 1:8 twice a week.
Preparation of conditioned medium. For constitutive L -6 production, osteosarcoma cell lines were seeded in 24-well plates (Costar, Cambridge, MA) at the concentration of 4 X lo4 cells per well in RPMI 1640 with 2% FCS. After 48 hours, the supernatants were collected for IL-6 determination. For IL-6 secretion in coculture system, MG63 and Saos-2 were seeded at 2.5 X 104/cmZ in RPMI 1640 with 2% FCS, and 1.25 X lo5 or 5 X 10' XGl cells were added directly to the culture or placed in a transwell insert in 96-and 24-well plates, respectively. After 48 hours of coculture, the supernatants were collected and centrifuged to discard cells, and cell debris and aliquots were kept frozen until IL-6 determination.
For osteocalcin production, MG63 and Saos-2 were seeded at 1.75 X IO4 cells per well in 96-well plates in RPMI 1640 with 10% FCS. After 24 hours, the supernatant was removed and replaced by fresh medium containing 2% FCS with 8 X m o m 1,25-(OH)zD3. After 48 hours, supernatants were collected for osteocalcin determination.
Isolation of CD56+ and CD56-populations in the XGI myeloma cell line. Positive and negative populations for CD56 were selected using magnetic beads coated with a goat anti-mouse IgG and preincubated with an anti-CD56 antibody according to the manufacturer's procedure (Immunotech). The positive and negative populations were obtained as described above and then cultured for several days before being tested for CD56 expression. The selection of populations was repeated until pure populations were obtained.
Paraformaldehyde and bromelain treatments. Cells ( IO6) were mildly fixed for 10 minutes in phosphate-buffered saline (PBS), I % paraformaldehyde at 4°C and then washed three times in PBS. Myeloma cells (IO6) were incubated for 20 minutes at 37°C with 5 U bromelain (Sigma, St Louis, MO) in 2.6% glycerol and PBS at a ratio of 9: I, as previously d e~c r i b e d .~~
The bromelain treatment does not alter the cell viability.
IL-6 determination. Supernatants were tested by enzyme-linked immunoadsorbent assay (ELISA) using a commercially available kit for IL-6 (Innotest, Besanqon, France). This assay measured IL-6 concentrations ranging from 10 to 500 pg/mL.
Osteocalcin production. Supernatants were tested by ELISA using a commercially available kit for osteocalcin (Osteometer, Herlev, Denmark). This assay only measured intact osteocalcin concentrations ranging from 0.2 to 32 nglmL.
Flow cytometric analysis. For immunofluorescence staining of myeloma cell lines, 5 X lo' cells were incubated with different MoAbs for 30 minutes at 4°C then with a goat anti-mouse fluorescein isothiocyanate (FITC)-conjugated MoAb (Immunotech).
Confluent osteoblastic cells were detached from the flask after an incubation in PBS with 1 mmo" EDTA for 30 minutes at 37°C and were then washed in PBS before being used for immunofluorescence staining as described above for myeloma cells.
Adhesion assay. Adhesion was quantified by flow cytometry as described by Ahsmann et al.M Myeloma cells (lo6) were incubated with 5 HL 6-carboxyfluorescein diacetate (6-CFDA; 1 mg/mL; Calbiochem, San Diego, CA) for 30 minutes at 37°C. This labeling procedure is 100% efficient. The cells were washed twice in PBS and then resuspended in culture medium. Myeloma cells (2 X IO') were added to 3.5 X IO4 adherent osteoblastic cells. After a 2-hour incubation, the nonadherent myeloma cells were removed by carefully rinsing the plates three times with PBS at room temperature. After the final wash, 250 pL of trypsin EDTA solution was added for 2 minutes. Then the plates were put on ice, and 50 pL FCS was added. Cells were vigorously resuspended and analyzed by flow cytometry. The fluorescent myeloma cells were easily distinguished from the osteoblastic cells by side light scatter and fluorescence properties, allowing quantification of adhesion.
RESULTS

Constitutive secretion of IL-6 by Saos-2 and MG63 cells
is upregulated in coculture systems with XG1 myeloma cells.
We first examined the steady IL-6 production of the two osteoblastic cell lines Saos-2 and MG63. The levels of IL-6 production by MC63 were weak (30 2 28 pg/mL per 2 X lo4 cells) and close to the sensitivity of our ELISA, while Saos-2 constitutively secreted higher levels of IL-6 (235 2 50 pg/mL per 2 X lo4 cells). Previous studies have shown that the production of IL-6 by fibroblastic stromal cells could be positively modulated by myeloma cells; thus, in this study, we have investigated in a coculture system with osteoblastic cells whether myeloma cells dependent on IL-6 for growing could regulate IL-6 secretion by osteoblastic cells. As shown in Fig 1, the results have demonstrated that the coculture of Saos-2 cells with an increasing number of XG1 cells resulted in an upregulation of L -6 secretion by Saos-2. A twofold increase of IL-6 production was observed after addition of lo5 XG1 cells, and the IL-6 production was maximal (sixfold) after the addition of 5 X lo5 XG1 cells. When more than 5 X lo' XG1 cells were added, the IL-6 production curve reached a plateau, probably resulting from a balance between the maximum IL-6 production and the use of IL-6 for XGl growth. To demonstrate that osteoblastic cells were responsible for enhanced L 6 production, the Saos-2 or the XG1 cells in the coculture system were mildly fixed by paraformaldehyde treatment. When the Saos-2 cells were fixed, no IL-6 was detectable in the supernatant of the coculture. On the other hand, the fixed XG1 cells in the coculture were still able to upregulate the IL-6 production by Saos-2, clearly indicating that Saos-2 cells were responsible for the IL-6 production (results not shown). Similarly, XG1 cells in a coculture system with MG63 cells positively modulated the IL-6 production by MG63 by 8-fold to 11-fold. In contrast with XG1, the XG6 myeloma cell line was not able to upregulate the production of IL-6 by MG63 or Saos-2 (results not shown).
Cell-to-cell contact between myeloma cells and Saos-2 cells is required for optimal IL-6production by Saos-2 cells. To evaluate the requirement of myeloma cell adhesion to Saos-2 for IL-6 upregulation, the XGl myeloma cells were placed in transwell inserts and added to the Saos-2 cell culture. This coculture in the absence of cellular contact resulted in weak IL-6 induction compared with optimal IL-6 production obtained in a contact coculture system (Table 1 ). This finding indicated that a positive signal given by a soluble factor released by XGl cells in the absence of cellular con- tact was weak in comparison with the signaling triggered by the contact between myeloma and osteoblastic cells. Because of the importance of the physical interaction between myeloma cells and osteoblastic cells for the induction of IL-6, we compared the capacities of XG1 and XG6 cells to adhere to Saos-2 cells. Quantification of the adhesion was analyzed by flow cytometry, and the results indicated that XG1 cells adhere more strongly to Saos-2 than do XG6 cells (Fig 2) , indicating a possible correlation between adhesiveness and the capacity to stimulate L-6. To confirm this correlation, myeloma cells were treated by bromelain, a cysteine protease that removes many surface molecules, such as CD44, CDS6, and CDS4. After treatment, the XG1 cells have a strongly decreased capacity for both adhesion (Fig 2) and IL-6 stimulation (710 2 10 pg/mL of IL-6 for bromelain-treated XG1 cells v 3,040 ? 150 pg/mL for nontreated XG1 cells in coculture with Saos-2).
Adhesion molecule expression on osteosarcoma and myeloma cell lines. Because the adhesion of myeloma cells to Saos-2 cells appeared to be crucial for IL-6 upregulation, we investigated the expression of adhesion molecules on osteoblastic and myeloma cell surfaces to further analyze the potential adhesive interactions between myeloma and osteoblastic cells. As shown in Table 2 , MG63 and Saos-2 cells displayed the same adhesion molecule profile, with some differences in the levels of intensity. Briefly, the pattern of Saos-2 and MG63 adhesion molecules was CDS4+ (ICAM-l), CD49d+ (VLA4), CD49e' (VLAS), CD44+, and CDS6+ (NCAM), but these cells did not express the CDlla (LFA1) and CD106 (VCAM) molecules. The CD56 expression shown in Fig 3 indicated that Saos-2 cells expressed a high level of CDS6, while the CD56 expression level on MG63 cells was weaker. Three components of the ECM were also investigated; the results indicated that the osteoblastic cells secreted fibronectin and type I collagen but not laminin (Table 2) . On the other hand, the phenotype of myeloma cells revealed that both cell lines expressed CD%, CD44, CD49d, and CD54 but not CD49e and CD1 l a ( Table   For personal 3). The level of expression of CD44, CD49d, and CD54 was higher on XG1 cells than XG6 cells. Moreover, in contrast with XG6 cells, which were negative for CD56, XG1 cells expressed this antigen on a large subpopulation (80%). The differences in XG1 and XG6 phenotypes are in good agreement with their respective capacities for adhesion on Saos-2 cells.
Role of CD56 molecules in the interaction between XGI and Saos-2 cells. CD56 represented the major difference in the adhesion molecule profile between XG1 and XG6 cells. Moreover, XG1 cells presented two distinct populations for CD56 expression, as 80% of the cells expressed CD56. Because CD56 was expressed on both XGl and Saos-2 cells and because it is responsible for homotypic adhesion, we investigated the potential involvement of this molecule in the stimulation of IL-6 production by Saos-2 cells. The addition of CD56 MoAb in our coculture system induced a significant and reproducible reduction of IL-6 stimulation by 25% t-5% (P < .01) because an irrelevant antibody had no effect (Fig 4A) . To better investigate the function of CD56, we next analyzed individually the CD56+ and CD56-XGl subpopulations obtained after positive and negative selection, respectively. These cell subpopulations were stable for CD56 expression over several months, and the other adhesion molecules tested (CD58, CD44, CD49d, CD54) were identically expressed in both cell subpopulations. The CD56 expression on these two XG1 subpopulations is shown in Fig 5. Although the two XG1 subpopulations induced an upregulation of IL-6 production, we found that this upregulation was more marked with the CD56+ cell subpopulation than with the CD56-cell subpopulation (Fig 4B) . Thus, using two different approaches to explore the CD56 function, we concluded that CD56 was involved in the ability of myeloma cells to interact with Saos-2 cells. 
Effect of anti-CD29, anti-CD44, and anti-jibronectin MoAb addition in the interaction between XGl and Saos-2
cells.
A potential adhesive interaction between Saos-2 and XG1 cells via fibronectin was compatible with the production of fibronectin by Saos-2 cells (Table 2 ) and with the expression of CD49d on myeloma cells (Table 3) . Therefore, we further examined the effects of addition of anti-CD29 (K20) or anti-fibronectin (120.5) MoAb on the IL-6 secretion by Saos-2 cells in the coculture system (Fig 6) . A 25% t-4% (P < .01) inhibitory effect on the IL-6 production by the anti-fibronectin antibody was seen in the coculture system in contrast with the K20 antibody, which had no effect (Fig 6) . Because it has been demonstrated that CD44 may be critically important for cell-to-cell and cell-to-ECM recognition, we also examined the ability of anti-CD44 MoAb to inhibit IL-6 production. As shown in Fig 6, we found that, of all the antibodies tested, anti-CD44 MoAb had the most important inhibitory effect: 37% 2 14% (P < .05). A very weak additional effect, ie, 47% 2 4% (P < .Ol), was observed with the combination of anti-CD44, anti-CD56, and anti-fibronectin MoAbs, suggesting that other molecules were involved in this interaction process.
Osteocalcin synthesis in M M 3 and Saos-2 cells is dependent on 1,25-(OH),D3.
Osteocalcin, which is synthesized in vivo by osteoblasts exclusively, has been shown to be produced by MG63 cells. This osteocalcin production by MG63 cells was demonstrated to be dependent on 1,25-(oH),D3 ?3 In this study, we first compared the MG63 and Saos-2 cells for their basal levels of osteocalcin and for their response to 8 X lo-* m o m 1,25-(0H)&. For this purpose, the cells were cultured for 24 hours in 10% FCS, and then fresh medium with 2% FCS was added in the presence or absence of 1 ,25-(OH),D3. Determination of osteocalcin in the respective conditioned media of MG63 and Saos-2 c u l t u~s indicated that MG63 and Saos-2 cells secreted low to undetectable levels of osteocalcin, but 1,25-(OH)2D3 treatment increased osteocdcin production up to 17.2 ? 2.8 @mL per 1 6 cells and 3.9 t-1.2 ng/mL per 1 6 cells per 48 hours for MG63 and Saos-2 cells, respectively. Moreover, we demonstrated that the MG63 osteocalcin production dependent on 1,25-(OH),D3 is upregulated by IGF-1 and insulin. The addition of 50 ndml IGF-1 or 2 X m o m insulin in MG63 culture induced a one-third increase of osteocalcin production. These last findings are in agreement with the upregulation induced by IGF-1 and insulin in normal osteoblasts."' XGl and XG6 cells reduce the level of osteocalcin in the MG63 culture in part by the secretion of a soluble factor. We next used MG63 cells, which allowed a more significant response to 1,25-(OH),D3 than Saos-2 cells. We determined (Fig 7) .
To determine whether the contact of myeloma cells with MG63 cells was necessary to induce a reduction of the osteocalcin level or not, XGI and XG6 cell culture supernatants were added to the MG63 culture. The results in Fig 7 indicate that supernatants of XGl and XG6 cell culture were able to reduce the osteocalcin level by 52% t 10% and 50% 2 9%, respectively, demonstrating that a large part of the reduction was induced by a soluble factor. Moreover, the inhibition due to the addition of XGI and XG6 supernatants was totally suppressed when the supernatants were denaturated by heat treatment (results not shown).
Addition of exogeneous IL-6 downregulated osteocalcin production but was not responsible for the inhibition observed in the coculture qwern. We next investigated whether rIL-6 exerted a regulation on the osteocalcin secretion by MG63 cells. IL-6 at 2 ng/mL inhibited osteocalcin secretion by 48% t 5%, showing that the osteocalcin secretion is highly regulated by the addition of exogeneous IL-6 (Fig 7) . Moreover, a neutralizing anti-IL-6 MoAb (BE8) in the MG63 culture induced an increase in the osteocalcin production (Fig 7) . This last result seems to indicate that endogenous IL-6 is able to downregulate osteocalcin. Thus, the downregulation observed with endogeneous IL-6 is also observed with exogeneous IL-6. Because IL-6 is present in the culture of MG63 (40 t 15 pg/mL) and induced in the coculture with XGI myeloma cells (480 t 70 pg/mL), we tested the effect of an anti-IL-6 MoAb (BE8) in the coculture system. As shown in Fig 7, weak reversion of osteocalcin inhibition was observed for XGI and XG6 cells, indicating that the implication of IL-6 on the inhibition of osteocalcin production in the coculture system was weak. 
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DISCUSSION
The bone marrow environment is believed to regulate the development and growth of myeloma cells and to play an important role in the pathophysiology of MM. A variety of cell types including macrophages, fibroblasts, endothelial cells, and bone cells are the principal components of the bone marrow environment. The heterogeneity of the adherent layer obtained after long-term bone marrow culture42 provides a too complex system for elucidating the nature of the respective role and interaction of each component with myeloma cells. Bone destruction is a hallmark of MM. In vivo, malignant plasma cells grow in the close vicinity of bone trabeculae, stimulating bone resorption while inhibiting bone formation. This uncoupling process is sufficient to explain the occurrence of lytic bone lesion^.^ Physiologically, osteoblasts play a critical role in bone remodeling. They are not only involved in bone formation by producing collagen and noncollagenic proteins such as the major one, osteocalcin, but also in bone resorption by releasing several proteins and soluble factors necessary for the recruitment and activation of osteoclast^."'^ Therefore, considering the pivotal role of osteoblasts in bone remodeling, and to more directly investigate the relation of myeloma cells to such osteoblasts, we have developed a coculture system between IL-6-dependent myeloma cell lines and osteoblastic cell lines. In the current study, we have clearly demonstrated that the contact of myeloma cells with osteoblastic cells could modify the osteoblastic cell biology by regulating both IL-6, a potent myeloma cell growth factor and osteoclast-activating factor, and osteocalcin, a noncollagenic protein essential for the process of bone formation.
An upregulation (6-fold to IO-fold) of osteoblastic IL-6 secretion was induced by XG 1 myeloma cells. In our experience, this critical observation is not restricted to human osteoblasts; indeed, using different stromal cells from long-term bone marrow culture of both healthy donors and myeloma patients, we
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Control rnAb both myeloma cells and exogeneous IL-6 can dramatically reduce the level of osteocalcin produced by osteoblastic cells. In summary, the reduction of osteocalcin concentration and the upregulation of IL-6 synergize to favor the formation of bone lesions, ie, by reducing the formation of bone matrix and by triggering both recruitment and activation of osteoclasts.
Although the myeloma cell line XG6 has lost its capacity to upregulate IL-6 production by osteoblastic cells, preliminary results indicate that all fresh purified myeloma cells, including those from plasma cell leukemia are capable of upregulating IL-6 production (results not shown). In the present report, we first provide evidence that physical contact IL6 production ("h of control)
was required for regulating IL-6 production by osteoblastic cells, and then we stress the importance of the adhesion have also confirmed that XGl cells induced triggering of IL-6 by stromal cells with a weak stimulation (1 .Zfold to 2-fold; unpublished d a a June 1995). These data are in agreement with previous studies, clearly demonstrating that human myeloma cells induce IL-6 triggering in stromal cells (2-fold to 3.4-fold).Ls2L However, we note that the stimulation of stromal cell L 6 production was inferior to that obtained with osteoblastic cells (6-fold to 10-fold). Indeed, this local increase in IL-6 production may have two important consequences for the biology of MM. The first is to facilitate the growth of myeloma cells, which, in most cases, is considered to be IL-6-dependent.I4 The second is to increase bone resorption, a major feature of MM, by triggering osteoclast recruitment and activation essentially through I L -~. " s~~ The production of osteocalcin, the major noncollagenic protein of bone matrix, appears to be an excellent indicator of bone formation.'" Our data suggest that ability of myeloma cells to osteoblastic cells. Based on the difference between XG1 and XG6 cells in terms of CD56 expression and with regard to their ability or inability to upregulate IL-6, it was tempting to speculate that CD56 could play an important role in the IL-6 triggering. Although the murine stromal cells have been described as expressing CD56,44 no evidence of a functional role has previously been described for this molecule. In this study, we have demonstrated that CD56 expressed on both osteoblastic and XGl myeloma cells could mediate an adhesive interaction between both cell types. However, the fact that the CD56-negative XG1 cell subpopulation was still able to trigger IL-6 upregulation excluded the possibility that the CD56 molecule transduced a positive signal for IL-6. Nevertheless, the IL-6 triggering was less potent than for the XG1 cells expressing CD56, clearly underlying the importance of CD56 interaction between myeloma and osteoblastic cells. Notably, although CD56 expression on normal osteoblastic cells has not yet been documented, CD56 has already been found on normal osteoblasts from other species!'
Considering the very fine regulation of CD56 expression in MM, ie, upregulation on myeloma cells during chronic and accelerated phases and then downregulation during the extramedullary phase of the disease, it will be of major interest to further investigate CD56 expression on normal human osteoblastic cells. If expressed, CD56 would be a key molecule for the interactions between myeloma cells and the bone environment. Despite our incomplete knowledge of the other molecules responsible for the interactions between osteoblasts and myeloma cells, our study has shown that, at least, the molecules CD44 and CD49d were also involved in the adhesive interactions. These findings confirmed the other recent observation showing that CD49d was involved in the interaction between stromal cells and myeloma cell^.'^^^' We also found a strong inhibitory effect on the IL-6 production induced by the CD44 MoAb in our coculture system similar to that observed by Lokhorst et a l Z o in another coculture system with stromal cells. Moreover, this finding can be related to the fact that CD44 partly mediated the physical contact responsible for the growth of murine plasmacytoma on stromal cells" and also to the fact that CD44 blocked the lymphopoiesis in long-term bone marrow cultures. 46 It is likely that such interaction does occur at different stages of the B-cell differentiation and plays an important function.
A last point deserves some comment. Our data support 
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the hypothesis that myeloma cells decrease the amount of intact osteocalcin measured in the coculture supernatant mainly via a soluble factor and also in part via cell-to-cell contact. On one hand, we have shown that exogeneous IL-6 inhibited the osteocalcin in MG63 cell culture, and on the other hand, we observed a small increase of osteocalcin production in MG63 culture with an anti-IL-6 MoAb, indicating that endogenous IL-6 was also able to downregulate osteocalcin levels. However, a pivotal role for IL-6 in our coculture system could be excluded by the weak reversion of the inhibition observed when the coculture was performed in the presence of a neutralizing anti-IL-6 MoAb. IL-l and tumor necrosis factor a (TNFa) have been previously shown to inhibit osteocalcin production; however, in this coculture system, no detectable IL-I or TNFa secretion were demonstrated (results not shown). Although the explanation for this negative osteocalcin regulation remains currently unknown, preliminary results support the idea that a protease could be involved in this process. It is of particular interest that the osteocalcin inhibition induced by XGI cells is more important than that induced by XG6 cells. This observation could be related to the strong adhesiveness of XGI cells to osteoblastic cells and may represent the part of the inhibition induced by cell-to-cell contact. In addition, we observed that Daudi and Raji, two malignant B cell lines, were also able to negatively modulate the osteocalcin level. However, the capacity of Burkitt lymphoma cell lines to inhibit osteocalcin production does not confer on these cells the capacity to induce bone lesions. Indeed, concomitant events are required for the emergence of bone lesions, and only the myeloma cells combined those events, ie, medullary localization and proliferation close to the bones, capacity to stimulate the bone marrow microenvironment to produce their own growth factor (IL-6), which is also an osteoclast-activating factor, and limiting the availability of osteocalcin for the bone formation process.
On MG63 cells, the downregulation of osteocalcin secretion by exogeneous IL-6 raises the hypothesis that IL-6 may inhibit bone formation, but further investigations are required on normal human osteoblastic cells to support this hypothesis. Moreover, these results were in agreement with those of Li and Stashenko4' demonstrating that IL-6 downregulates osteocalcin in rat osteoblastic cells but were in contrast to those of Littlewood et aI4' demonstrating that osteoblastic cells do not respond to IL-6. Collectively, these data support the idea that the bone marrow environment, especially the bone environment, is directly and specifically modified in the close vicinity of myeloma cells in vitro, ie, in a fashion relevant to the major characteristics observed in vivo in patients with MM: the preferential growth of myeloma cells in the close vicinity of bone cells, the excessive osteoclastic resorption around myeloma cells with inhibition of bone formation, and the frequent abnormally high IL-649 and low osteocalcinsO production, respectively.
